JMPWA
BMRN icon

JP Morgan Private Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$5.95M Buy
+67,207
New +$5.98M 0.02% 471
2023
Q2 		– Sell
-14,764
Closed -$1.44M – 1531
2023
Q1 		$1.44M Buy
14,764
+1,691
+13% +$175K ﹤0.01% 1005
2022
Q4 		$1.35M Buy
13,073
+1,221
+10% +$115K ﹤0.01% 1008
2022
Q3 		$1M Buy
11,852
+1,474
+14% +$131K ﹤0.01% 1134
2022
Q2 		$860K Sell
10,378
-3,117
-23% -$248K ﹤0.01% 1215
2022
Q1 		$1.04M Buy
13,495
+2,306
+21% +$193K ﹤0.01% 1206
2021
Q4 		$989K Sell
11,189
-2,156
-16% -$178K ﹤0.01% 1248
2021
Q3 		$1.03M Buy
13,345
+3,041
+30% +$240K ﹤0.01% 1194
2021
Q2 		$860K Buy
10,304
+2
+0% +$159 ﹤0.01% 1260
2021
Q1 		$778K Sell
10,302
-2,045
-17% -$167K ﹤0.01% 1148
2020
Q4 		$1.08M Sell
12,347
-1,594
-11% -$126K ﹤0.01% 976
2020
Q3 		$1.06M Buy
13,941
+1,385
+11% +$140K ﹤0.01% 869
2020
Q2 		$1.55M Buy
12,556
+2,611
+26% +$259K 0.01% 656
2020
Q1 		$840K Buy
9,945
+1,205
+14% +$104K ﹤0.01% 764
2019
Q4 		$739K Buy
8,740
+1,026
+13% +$77.5K ﹤0.01% 903
2019
Q3 		$520K Buy
7,714
+880
+13% +$67.8K ﹤0.01% 989
2019
Q2 		$585K Buy
6,834
+887
+15% +$75.9K ﹤0.01% 926
2019
Q1 		$528K Buy
5,947
+1,780
+43% +$165K ﹤0.01% 1016
2018
Q4 		$355K Sell
4,167
-3,017
-42% -$287K ﹤0.01% 1090
2018
Q3 		$696K Buy
7,184
+434
+6% +$43.3K ﹤0.01% 953
2018
Q2 		$636K Sell
6,750
-367
-5% -$32.1K ﹤0.01% 924
2018
Q1 		$577K Buy
7,117
+4,503
+172% +$386K ﹤0.01% 821
2017
Q4 		$233K Buy
2,614
+245
+10% +$21.3K ﹤0.01% 1136
2017
Q3 		$220K Buy
+2,369
New +$209K ﹤0.01% 1126
2015
Q3 		– Sell
-1,585
Closed -$217K – 1065
2015
Q2 		$217K Buy
+1,585
New +$196K ﹤0.01% 948

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Private Wealth Advisors's BMRN Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2023: 67,207 shares worth $5.95M. The stake represents 0.02% of the portfolio and ranks #471 among its holdings. This is a return to the name: JP Morgan Private Wealth Advisors previously reported a position in BMRN as recently as Q1 2023.

JP Morgan Private Wealth Advisors first reported a position in BMRN in Q2 2015 and has held it in 25 quarters since. 520 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 67,207 shares of BioMarin Pharmaceuticals worth $5.95M as of Q3 2023.
  • BioMarin Pharmaceuticals was a new JP Morgan Private Wealth Advisors position in Q3 2023.
  • BioMarin Pharmaceuticals made up 0.02% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #471 holding.
  • JP Morgan Private Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2015 and has held it in 25 quarters since.
  • 520 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.